DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
DA Davidson analyst Linda Bolton Weiser maintains a Neutral rating on Usana Health Sciences (USNA) and lowers the price target from $53 to $48.
February 22, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
DA Davidson analyst maintains a Neutral rating on Usana Health Sciences and lowers the price target from $53 to $48.
The reduction in price target by DA Davidson suggests a less optimistic outlook on Usana Health Sciences' stock value in the short term, potentially leading to a negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100